Visual field changes after intravitreal injections of Bevacizumab for neovascular age-related macular degeneration

Jun-yi WANG,Guo-ge HAN,Chang-zheng CHEN,Yi-qiao XING,Zeng-ping LIU,Fei XU
DOI: https://doi.org/10.3760/cma.j.issn.1006-4443.2010.06.017
2010-01-01
Abstract:Objective To evaluate visual field changes every time after systemic bevacizumab (Avastin) therapy in patients with choroidal neovascularization (CNV) related age-related macular degeneration (ARMD). Methods Single-center, uncontrolled clinical study. Thirteen CNV related ARMD patients (15 eyes) with best-corrected visual acuity (BCVA) more than 0.1 were determined by indirect ophthalmoscope, fundus fluorescein angiography (FFA) and optic coherence tomography (OCT). All these eyes were underwent 6 times intravitreal injections of bevacizumab (1.25mg, 0.05ml) at 6 w to 12 w intervals. The follow-up investigation time was from 3 to 12 months. Record and analyze the mean visual sensitivity (MS), mean defect (MD) and loss variance (LV) changes before and 6w, 12w. 24w, 48w after injections. Results Take 0 week as a baseline, we found MS values of 24th week and 48th week revealing a remarkable increase (t values were 2.91, 3.69 respectively, P<0.05). MD values at 48th week decreased when compared with that at 0 week (t value was 1.35, P <0. 05). There were no statistically significant differences when compared LV values within these groups. Conclusions Repeatedly intravitreal injections of bevacizumab are benefit for visual acuity of neovascular ARMD, especially changes in MS and MD values of macular retina. Visual acuity would improve in most of the neovascularization ARMD after 4-6 times injections.
What problem does this paper attempt to address?